Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Notes Payables (2020 - 2021)

Cyclerion Therapeutics (CYCN) has disclosed Notes Payables for 2 consecutive years, with $3.5 million as the latest value for Q3 2021.

  • For Q3 2021, Notes Payables changed 0.0% year-over-year to $3.5 million; the TTM value through Sep 2021 reached $3.5 million, changed 0.0%, while the annual FY2020 figure was $3.5 million, N/A changed from the prior year.
  • Notes Payables hit $3.5 million in Q3 2021 for Cyclerion Therapeutics, roughly flat from $3.5 million in the prior quarter.
  • Across five years, Notes Payables topped out at $3.5 million in Q2 2020 and bottomed at $3.5 million in Q2 2020.